NCT07128199
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07128199
Title A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection (REZILIENT4)
Acronym REZILIENT4
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Taiho Oncology, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | TUR | ROU | POL | NLD | ITA | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG


No variant requirements are available.